Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PCSK9 Patent Battle: Amgen Seeks Supreme Court Review Ahead Of February Trial

Sep 07 2018

• By Brenda Sandburg

Supreme Court long shot

Related Content

Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It

May 01 2018

Patent Claims Must Be Written Narrowly, Federal Circuit Reaffirms In Ariad v. Lilly

Mar 22 2010

PCSK9 Inhibitor Labeling Parity Is Within Reach As Praluent And Repatha Strive To Make Commercial Case

Aug 20 2018

PCSK9 Patent Case: Praluent Injunction Vacated, But May Well Return

Oct 06 2017

‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales

Jan 06 2017

Patent Settlement Offers Some Salve For Bristol’s PD-1 Wounds

Jan 21 2017

Lilly Laid Groundwork For Abbott's Defeat Of J&J's Patent Verdict On Humira

Feb 28 2011

Praluent Fate Uncertain After Amgen Wins PCSK9 Patent Battle

Mar 17 2016

Related Companies

Amgen, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

ARIAD Pharmaceuticals, Inc.

Eli Lilly and Company

Abbott

AbbVie Inc.

Johnson & Johnson

Bristol Myers Squibb Company

Merck & Co., Inc.

Ono Pharmaceutical Company, Ltd.

Express Scripts Holding Company

Additional Topics

United States Intellectual Property Legal Issues Policy Biologics Cardiovascular BioPharmaceutical

More from Legal & IP

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window